Technology

In the second part of this roundtable discussion, experts discuss how the industry is handling AI in the marketing space.

AI provides opportunities to bring people together—not replace them.

Because the AI space is changing rapidly, it’s essential that companies are budgeting correctly and using their investments strategically.

In this first part of this roundtable discussion, experts discuss the current perception of AI and how this is impacting adoption.

EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Pleio’s chief experience officer discusses why these platforms are being embraced by the industry.

Pharma looks to take advantage of expanded access programs across Asia-Pacific region.

The alliance’s president discusses the current state of data sharing, security concerns, and the adoption AI.

Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.

Slope’s CEO and co-founder discusses technological advances that are solving problems with data collection and sorting from clinical trials.

Practical ways product teams can leverage the benefits of generative artificial intelligence as a strategic advantage in pharmaceutical and life sciences commercialization.

Announcements such as Apple’s come with pros and cons for industry.

Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.

Webinar Date/Time: Thu, Oct 17, 2024 11:00 AM EDT

Dr. Cherukuri discusses the impact of Apple’s new AirPods and their ability to be used as hearing aids.

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Pharma companies are facing a higher number of incredibly destructive cyber-threats than ever before.

Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST

A C-suite Q&A with Cristina Ortega Duran, President of Evinova.

The Dandelion Health CEO discusses the collection and analysis of data in the digital world.

Webinar Date/Time: Wednesday, September 25th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Hersh Sagreiya at the Hospital of the University of Pennsylvania.

Datapharm’s CEO discusses ways to improve access and accuracy for healthcare professionals and patients.

Achieving better outcomes for patients and advancing the fields of nuclear medicine and oncology are not just about adopting new technologies, but also about embracing a profound change in how care is delivered.

The technology has the potential to be implemented across multiple aspects of the industry.

A Harvard Business School Healthcare Alumni Association Q&A with Kevin Werbach, Professor of Legal Studies and Business Ethics at the Wharton School.

Culjat discusses FDA’s new draft framework on PDURS.